OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non‐critical COVID‐19 pneumonia: A double‐blind randomized, placebo‐controlled clinical trial
Faranak Sedighi, Mehran Zarghami, Fatemeh Alizadeh Arimi, et al.
Neuropsychopharmacology Reports (2023) Vol. 43, Iss. 2, pp. 202-212
Open Access | Times Cited: 6

Showing 6 citing articles:

The efficacy and safety of ginger (Zingiber officinale) rhizome extract in outpatients with COVID-19: A randomized double-blind placebo-control clinical trial
Ali Ameri, Mehdi Farashahinejad, Parivash Davoodian, et al.
Medicine (2024) Vol. 103, Iss. 22, pp. e38289-e38289
Open Access | Times Cited: 3

Antidepressants for prevention of severe COVID-19, Long COVID and outlook for other viral diseases
Udo Bonnet, Georg Juckel, Jens Kuhn
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 2

In vitro and in vivo modulatory effects of fluoxetine on gene expression and antioxidant enzymes in CFA-induced chronic inflammatory model: drug repurposing for arthritis
Hafiz Muhammad Irfan, Awais Anjum, Mulazim Hussain Asim, et al.
Inflammopharmacology (2024) Vol. 32, Iss. 5, pp. 3429-3441
Closed Access | Times Cited: 1

Die Bedeutung von Antidepressiva bei COVID-19 und Long-COVID – Ein Scoping-Review Update
Udo Bonnet, Georg Juckel
Fortschritte der Neurologie · Psychiatrie (2024)
Closed Access | Times Cited: 1

Efficacy and safety of deferoxamine in moderately ill COVID-19 patients: An open label, randomized controlled trial
Ali Ameri, Farnaz Pourseyedi, Parivash Davoodian, et al.
Medicine (2024) Vol. 103, Iss. 34, pp. e39142-e39142
Open Access

Page 1

Scroll to top